Despite its potential as a therapeutic target, there are challenges in targeting CXCR4. One major hurdle is the widespread expression of CXCR4 in normal tissues, which can lead to off-target effects and toxicity. Additionally, cancer cells can develop resistance to CXCR4 inhibitors by utilizing alternative signaling pathways. Therefore, combination therapies that target multiple pathways might be necessary to overcome these challenges.
